PLOS is a non-profit organization on a mission to drive open science forward with measurable, meaningful change in research publishing, policy, and practice.

Building on a strong legacy of pioneering innovation, PLOS continues to be a catalyst, reimagining models to meet open science principles, removing barriers and promoting inclusion in knowledge creation and sharing, and publishing research outputs that enable everyone to learn from, reuse and build upon scientific knowledge.

We believe in a better future where science is open to all, for all.

Journals
More Content
More About Collections
collection

Targeted Anticancer Therapies and Precision Medicine in Cancer

Calls for Papers Collections

While the rate of death from cancer has been declining since the 1990s, an estimated 9.6 million people died from cancer in 2018, making it the second-leading cause of death worldwide. There is clearly still an unmet need to improve cancer detection and bring new treatment options to patients. These articles in this Collection represent diverse facets of ongoing efforts in this area, where general knowledge of cancers serves to inform individual patient’s care, and - at the same time - particulars from individual cancer cases contribute to improved resolution of our general knowledge pool.

Image Credit: https://www.flickr.com/photos/nihgov/27786378828/

Jump to section
Guest Editors (PLOS ONE)
  • Image credit
    PLOS ONE
    The PLOS ONE Blog Introducing the Targeted Anticancer Therapies and Precision Medicine in Cancer Collection | EveryONE: The PLOS ONE blog
    November 18, 2019 PLOS ONE
  • Image credit
    https://collections.staging.plos.org/s/targeted-anticancer-therapies
    Andrew Cherniack Andrew Cherniack
    March 13, 2019 Guest Editor, PLOS ONE
  • Image credit
    https://collections.staging.plos.org/s/targeted-anticancer-therapies
    Anette Duensing Anette Duensing
    March 13, 2019 Guest Editor, PLOS ONE
  • Image credit
    https://collections.staging.plos.org/s/targeted-anticancer-therapies
    Steven G. Gray Steven G. Gray
    March 13, 2019 Guest Editor, PLOS ONE
  • Image credit
    https://collections.staging.plos.org/s/targeted-anticancer-therapies
    Sunil Krishnan Sunil Krishnan
    March 13, 2019 Guest Editor, PLOS ONE
  • Image credit
    https://collections.staging.plos.org/s/targeted-anticancer-therapies
    Chandan Kumar-Sinha Chandan Kumar-Sinha
    March 13, 2019 Guest Editor, PLOS ONE
  • Image credit
    https://collections.staging.plos.org/s/targeted-anticancer-therapies
    Gayle E. Woloschak Gayle E. Woloschak
    March 13, 2019 Guest Editor, PLOS ONE
PLOS ONE Collection
Guest Editors (PLOS Computational Biology)
  • Image credit
    https://collections.staging.plos.org/s/targeted-anticancer-therapies
    Aaron Goldman Aaron Goldman
    March 13, 2019 Guest Editor, PLOS Computational Biology
  • Image credit
    https://collections.staging.plos.org/s/targeted-anticancer-therapies
    Feixiong Cheng Feixiong Cheng
    March 13, 2019 Guest Editor, PLOS Computational Biology
  • Image credit
    https://collections.staging.plos.org/s/targeted-anticancer-therapies
    Anna Panchenko Anna Panchenko
    March 13, 2019 Guest Editor, PLOS Computational Biology
  • Image credit
    https://collections.staging.plos.org/s/targeted-anticancer-therapies
    Benjamin Ribba Benjamin Ribba
    March 13, 2019 Guest Editor, PLOS Computational Biology
PLOS Computational Biology Collection
Follow PLOS on Twitter

To keep up to date on the latest research.

Follow us
View the original Call for Papers Announcement

This Call for Papers has closed, but PLOS ONE and PLOS Computational Biology are always open for submission.

view here
View our full list of Call for Papers

PLOS journals always have a number of active Calls for Papers in a wide range of subject areas.

view here
Back to top